Vertex Pharmaceuticals Incorporated Revenue 2008–2025
Vertex Pharmaceuticals Incorporated annual/quarterly revenue history and growth rate from 2008 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Vertex Pharmaceuticals Incorporated revenue for the quarter ending March 31, 2026 was 3.0 B, a 7.82% increase year-over-year.
- Vertex Pharmaceuticals Incorporated revenue for the twelve months ending March 31, 2026 was 11.8 B, a 11.39% increase year-over-year.
- Vertex Pharmaceuticals Incorporated annual revenue for 2025 was 12.0 B, a 8.90% increase from 2024.
- Vertex Pharmaceuticals Incorporated annual revenue for 2024 was 11.0 B, a 11.66% increase from 2023.
- Vertex Pharmaceuticals Incorporated annual revenue for 2023 was 9.9 B, a 10.51% increase from 2022.
- Vertex Pharmaceuticals Incorporated annual revenue for 2022 was 8.9 B.
Vertex Pharmaceuticals Inc. (VRTX) — Frequently Asked Questions
Vertex Pharmaceuticals Inc. (VRTX) is a publicly traded US company in the Healthcare sector. It has a market capitalization of $112.41B. In fiscal 2025 it reported revenue of $12.00B and net income of $3.95B. Explore VRTX's stock price, financial statements, earnings history, margins and key ratios below.
What is Vertex Pharmaceuticals Inc.'s market cap?
Vertex Pharmaceuticals Inc. (VRTX) has a market capitalization of $112.41B.
What is the VRTX stock price?
VRTX trades at $435.71 (-2.26% on the day).
How much revenue does Vertex Pharmaceuticals Inc. make?
Vertex Pharmaceuticals Inc. reported revenue of $12.00B in fiscal 2025.
Is VRTX profitable?
In fiscal 2025, Vertex Pharmaceuticals Inc. reported net income of $3.95B.
What is VRTX's P/E ratio?
Based on diluted EPS, VRTX has a price-to-earnings (P/E) ratio of about 28.4.